Dermatitis: Clinical Trials

3 trials for Dermatitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 enrolling by invitation. 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 33Enrolling by invitation 3

Follow Dermatitis: new trials by email Literature Review of Dermatitis trials Research Report on Dermatitis

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Oral or Topical Catechins for Radiation Dermatitis
Epicatechin, Epigallocatechin Gallate (EGCG), Microcrystalline Cellulose NF (placebo) - Radiation Dermatitis Acute, Radiation Dermatitis
Phase 3Enrolling by invitationCARLOS FRANCISCO SAAVEDRA GARCIA1622026-10-012026-09-11
A Phase III Clinical Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis.
10mg QY201 Placebo tablet, 20mg QY201 Placebo tablet, 10mg QY201 tablet - Atopic Dermatitis (AD)
Phase 3Enrolling by invitationE-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.4602025-03-122025-09-18
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Lebrikizumab, Placebo - Atopic Dermatitis, Eczema
Phase 3Enrolling by invitationEli Lilly and Company3382023-03-092026-10-26

Narrower conditions

Dermatitis, Atopic (2)  ·  Eczema (1)  ·  Fibrosis (1)  ·  Radiodermatitis (1)

Broader conditions

Skin Diseases (3)  ·  Skin and Connective Tissue Diseases (3)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2)  ·  Genetic Diseases, Inborn (2)  ·  Hypersensitivity (2)  ·  Hypersensitivity, Immediate (2)  ·  Immune System Diseases (2)  ·  Skin Diseases, Eczematous (2)  ·  Skin Diseases, Genetic (2)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)  ·  Radiation Injuries (1)  ·  Wounds and Injuries (1)

Interventions

Catechin (1)  ·  Sodium Chloride (1)  ·  epigallocatechin gallate (1)  ·  lebrikizumab (1)

Sponsors

CARLOS FRANCISCO SAAVEDRA GARCIA (1)  ·  E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. (1)  ·  Eli Lilly and Company (1)

Countries

Mexico (2)  ·  Argentina (1)  ·  Australia (1)  ·  Brazil (1)  ·  Canada (1)  ·  China (1)  ·  Czechia (1)  ·  France (1)  ·  Germany (1)  ·  Japan (1)  ·  Poland (1)  ·  Spain (1)  ·  Taiwan (1)  ·  United States (1)

Top investigators

Carmen Palacios, MD; PhD; MMSc; genetics (1)